Shishir Khetan, MD
Internal Medicine · Rockville, MDNPI 1861497372
Payments from drug & device makers
What this record shows
30 manufacturers reported payments, led by Merck at 40.2% of the total. Among internal medicine clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 151 payments — averaging $83.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$5K
- Modernatx, Inc.$2K
- Amgen$2K
- E.r. Squibb & Sons, L.L.C.$459
- Corcept Therapeutics$391
- Novo Nordisk$331
- plus $2K from 24 others
Across 5,658 payments — averaging $9206.85 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Modernatx, Inc.$49.1M
- Sanofi Pasteur Inc.$995K
- GSK$651K
- Janssen Research & Development, LLC$357K
- Pfizer$243K
- AstraZeneca$219K
- plus $551K from 9 others
What the payments were for
- Travel & lodging$6,75554%
- Food & beverage$5,82546%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 46 | $5,052 |
| Modernatx, Inc. | 20 | $2,396 |
| Amgen | 12 | $1,834 |
| E.r. Squibb & Sons, L.L.C. | 5 | $459 |
| Corcept Therapeutics | 3 | $391 |
| Novo Nordisk | 10 | $331 |
| AbbVie(2 entities) | 9 | $279 |
| Inspire Medical Systems, Inc. | 2 | $237 |
| Medtronic | 2 | $230 |
| Johnson & Johnson(2 entities) | 3 | $187 |
| AstraZeneca | 4 | $153 |
| Vivus LLC | 1 | $120 |
| Novartis | 1 | $118 |
| Exactech, Inc. | 1 | $114 |
| GSK | 3 | $110 |
| Pfizer | 8 | $108 |
| Gilead | 1 | $87 |
| Sanofi Pasteur Inc. | 3 | $61 |
| Boehringer Ingelheim | 2 | $46 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $41 |
| Astellas Pharma US Inc | 3 | $40 |
| Abbott | 2 | $38 |
| Teva Pharmaceuticals USA, Inc. | 1 | $28 |
| Lifescan, Inc. | 1 | $23 |
| Ironshore Pharmaceuticals Inc. | 1 | $22 |
| Ultragenyx Pharmaceutical Inc. | 1 | $19 |
| Lilly USA, LLC | 1 | $17 |
| Phathom Pharmaceuticals, Inc. | 1 | $16 |
| Biohaven Pharmaceuticals, Inc. | 1 | $14 |
| Dynavax Technologies Corporation | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,580 in reported general payments places this provider in the 95th percentile of 2,979 internal medicine providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 33 | $63,087 |
| MounjaroTirzepatide | 23 | $32,488 |
| JardianceEmpagliflozin | 18 | $29,418 |
| EliquisApixaban | 17 | $26,827 |
| SynthroidLevothyroxine Sodium | 56 | $4,676 |
| Atorvastatin Calcium | 207 | $3,971 |
| Rosuvastatin Calcium | 200 | $3,831 |
| Olmesartan Medoxomil | 76 | $2,461 |
| Metoprolol Succinate | 93 | $2,054 |
| Amlodipine Besylate | 196 | $1,605 |
| Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide | 12 | $1,527 |
| Risedronate Sodium | 15 | $1,484 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 12 | $1,420 |
| Losartan Potassium | 94 | $1,361 |
| Levothyroxine Sodium | 102 | $1,027 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $331 | $63,08733 claims |
| Lilly USA, LLCMounjaro | $17 | $32,48823 claims |
| Boehringer IngelheimJardiance | $46 | $29,41818 claims |
| PfizerEliquis | $108 | $26,82717 claims |
| AbbVieSynthroid | $279 | $4,67656 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,979 internal medicine providers in Maryland.
Other internal medicine in Rockville
- Scott KoenigRockville$20K
- Marianne MannHighland$2.1M
- Param DedhiaBaltimore$636K
- Curtis RosebraughAshton$418K
- Mark CorriereColumbia$402K
- Gregory PokrywkaTowson$377K
- Shawn DhillonBaltimore$227K
- Brian HarveyAnnapolis$220K
- Jeremy SugarmanBaltimore$210K
- Florence HounPotomac$161K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.